Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 6Hematologic Neoplasms 2Recurrence 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Biphenotypic, Acute 1

Interventions

fludarabine 52Cyclophosphamide 50venetoclax 48Azacitidine 46fludarabine phosphate 41Whole-Body Irradiation 33Specimen Handling 31Mycophenolic Acid 30Tacrolimus 28Melphalan 28Busulfan 27Cytarabine 25Stem Cell Transplantation 23Decitabine 23Biopsy 22Granulocyte Colony-Stimulating Factor 19Sirolimus 16Peripheral Blood Stem Cell Transplantation 16Filgrastim 16Thiotepa 15decitabine and cedazuridine drug combination 14Injections 14Cyclosporine 13ruxolitinib 9Methotrexate 9Mesna 9Hematopoietic Stem Cell Transplantation 9X-Rays 8Idarubicin 8Daunorubicin 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic Syndromes × Homoharringtonine × 1 year × Clear all
NCT04874194 2025-11-03

Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1

M.D. Anderson Cancer Center

Phase 1/2 Terminated
24 enrolled 15 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡